Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2020

Revenue from Contract with Customer [Abstract]

Disaggregation of revenue

Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.

In thousands of US dollars ($)	Three Months Ended June 30, 2020						Six Months Ended June 30, 2020
Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues
Product Sales – Point-in-time	$	182	$	182	$	—	$	381	$	381	$	—
License Fee – Over time	56		—		56		112		—		112
Total Drug Products	238		182		56		493		381		112
Concentrate Products
Product Sales – Point-in-time	15,168		13,319		1,849		30,280		26,826		3,454
License Fee – Over time	490		490		—		980		980		—
Total Concentrate Products	15,658		13,809		1,849		31,260		27,806		3,454
Net Revenue	$	15,896	$	13,991	$	1,905	$	31,753	$	28,187	$	3,566

In thousands of US dollars ($)	Three Months Ended June 30, 2019						Six Months Ended June 30, 2019
Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues
Product Sales – Point-in-time	$	15	$	15	$	—	$	15	$	15	$	—
License Fee – Over time	$	68	$	—	68		136		—		136
Total Drug Products	83		15		68		151		15		136
Concentrate Products
Product Sales – Point-in-time	14,268		12,822		1,446		29,264		25,746		3,518
License Fee – Over time	495		495		—		990		990		—
Total Concentrate Products	14,763		13,317		1,446		30,254		26,736		3,518
Net Revenue	$	14,846	$	13,332	$	1,514	$	30,405	$	26,751	$	3,654

Contract balances

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.

In thousands of US dollars ($)	June 30, 2020		December 31, 2019
Receivables, which are included in "Trade and other receivables"	$	3,565	$	4,203
Contract liabilities	$	11,084	$	12,076